| By Marketwire . | Article Rating: |
|
| August 31, 2012 08:30 AM EDT | Reads: |
167 |
CAMBRIDGE, MA -- (Marketwire) -- 08/31/12 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2012 Rodman & Renshaw Annual Global Investment Conference in New York, NY on Monday, September 10, 2012 at 10:25 a.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.
The presentation will be webcast live under the events section of Sarepta Therapeutics' website at www.sareptatherapeutics.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.
Sarepta Media and Investor Contact:
Erin Cox
425.354.5140
Email Contact
Published August 31, 2012 Reads 167
Copyright © 2012 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

